Therapy
Biotechnology
Medical

Adaptimmune Therapeutics

13,308

$10.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$6.21 (+127.78%) Today
-$0.68 (-6.14%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

CEO
Adrian Rawcliffe
Employees
400
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
1.44B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
12.21M
High Today
$12.77
Low Today
$7.80
Open Price
$10.11
Volume
113.53M
52 Week High
$12.77
52 Week Low
$0.709

Collections

Therapy
Biotechnology
Medical
Top Movers
Biopharmaceutical
Pharmaceutical
Cancer Prevention
Health

ADAP News

BloombergMay 29

Traders Sift Through Virtual Cancer Meeting’s Winners and Losers

(Bloomberg) -- Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presentin
2,130
ReutersMay 29

BRIEF-Spear T-Cells Targeting Mage-A4 Demonstrate New Responses In Esophagogastric Junction (Egj), Lung, And Head And Neck Cancers

May 29 (Reuters) - Adaptimmune Therapeutics PLC: * SPEAR T-CELLS TARGETING MAGE-A4 DEMONSTRATE NEW RESPONSES IN ESOPHAGOGASTRIC JUNCTION (EGJ), LUNG, AND HEAD
1,365

ADAP Earnings

-$0.33
-$0.22
-$0.10
$0.01
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Expected Jul 30, Pre-Market

You May Also Like

THO
SLM
IMOS
KZIA
WHLM
AVDE
SYX
RBC
KLDW
VKTXW
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy ADAP

Market Price$10.39
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell ADAP stock and options commission-free.
LearnBlogCareersHelpLog InSign Up